This is the first report on the long-term durability of response among complete responders to mitomycin C chemoablation of low-grade upper tract urothelial carcinoma.

Background and objective: To explore the risk factors and construct a prediction model of the lymphovascular invasion (LVI) in patients with upper tract urothelial carcinoma (UTUC). Methods: Clinical ...

Arnulf Stenzl and Alison Birtle debated whether neoadjuvant or adjuvant systemic therapy is best for high-risk upper tract urothelial carcinoma (UTUC) patients. Dr. Stenzl supported neoadjuvant ...

"For other health care professionals aiming to advocate for equitable changes within their system, it's really important to just start conversations about what you're noticing," says Hailey Frye.

Where are you using these treatments in your practice, and how do you choose between them for BCG-unresponsive patients? How have these advances changed the timing of radical cystectomy for patients?

The median progression-free survival was 45.3 months in the non-squamous cohort and 29.0 months in the cohort with squamous and non-squamous NSCLC cases. Pembrolizumab plus concurrent ...

FAPI PET/CT imaging results correlate with the Oxford classification MEST-C score for IgAN and might be used to monitor patients. Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may ...